Market Cap 90.31M
Revenue (ttm) 266.96M
Net Income (ttm) 28.51M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 10.68%
Debt to Equity Ratio -0.20
Volume 1,822,400
Avg Vol 1,708,078
Day's Range N/A - N/A
Shares Out 115.93M
Stochastic %K 30%
Beta 1.01
Analysts Strong Sell
Price Target $5.26

Company Profile

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigat...

Industry: Biotechnology
Sector: Healthcare
Phone: 650 649 3530
Address:
333 Twin Dolphin Drive, Suite 600, Redwood City, United States
Henry20feb_
Henry20feb_ Oct. 25 at 10:50 AM
$CHRS The Health Canada approval of LOQTORZI® (toripalimab) is a major milestone for Coherus BioSciences, expanding their immuno-oncology portfolio and strengthening their presence in the Canadian market. It provides a new treatment option for rare, aggressive cancers and opens opportunities for clinical collaborations, positioning Coherus for broader growth in oncology. (Thanks to ChatGPT)
1 · Reply
calibran_de
calibran_de Oct. 24 at 8:04 PM
0 · Reply
ITrustno1
ITrustno1 Oct. 24 at 8:01 PM
$CHRS low volume EOW finally, less than 50% avg. Earnings day variable on diff sites still: 11/6, & 2 sites showing 11/10th Fintel Reports -3.12% Short Interst for period ending 10/15/25 Borrow rate 1.35 Still over 30mill, but that’s 2straight months of negative SI (-2.44, -0.19, -2.29, & now -3.12) …& lowest total shares short since Jan 15th. Data share only: Do with it as you will.
1 · Reply
BMWLTWM3
BMWLTWM3 Oct. 24 at 6:29 PM
$CHRS what's up with you??
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Oct. 24 at 2:58 PM
$CHRS mm has nerfed all volatility. This shows the Penny stock rules. Jump up, retest down 35% down, jump up again, and settle into a wedge. Now chrs moving $0.04 cents today. Market likes $1.65-$1.68 where chrs is at cash $190-$200M market cap. Let's see if we close above 1.72
0 · Reply
normansteve
normansteve Oct. 24 at 2:09 PM
$CHRS It should be above $6, and here we are, at $1.X,65 😞 Someday we will see it above $6 💰
0 · Reply
normansteve
normansteve Oct. 24 at 2:07 PM
$CHRS Let's go, today +$1,80 🚀
0 · Reply
Gollum00
Gollum00 Oct. 24 at 2:05 PM
$CHRS how is this only up one cent with the news that just came out yesterday regarding Tori and Canada?
1 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Oct. 24 at 1:26 PM
$CHRS the stock will go up when no one expects it. They basically killing volatility more and more while volume decreases. Shorts are probably lots of mm who need to cover
0 · Reply
Jalu06
Jalu06 Oct. 24 at 12:23 PM
$CHRS I think 2026 can become transformational for coherus. Most important if coherus is participating at JPM Healthcare Conference in January and which timeslot they have. Unfortunately most of the HCC cases will have early response assessment so we can’t expect comparable complete responses rates. More important is I.e if less adverse events occur due to toripalimab in comparison with atezolizumab, this could hind for longer PFS and OS in later data cuts. CCR8 is something to watch in 2026, wen can expect some data readouts from major Pharma companies and I like the strategy „first to market“ in possible smaller indications, this could be of interest for mid sitze Pharma companies. I still assume that they have some kind of „pre deal“ with Junshi and Leo Pharma, but the real deal will only happen when the program is de risked and proof of concept is in. An other milestone payment could come in from GSK as the molecule name for SRF813 is Remzistotug
1 · Reply
Latest News on CHRS
Coherus Oncology: Five Readouts Or More Possible In 2026

Oct 1, 2025, 10:43 AM EDT - 24 days ago

Coherus Oncology: Five Readouts Or More Possible In 2026


Coherus Oncology: On The Shaping Up

Aug 25, 2025, 4:55 PM EDT - 2 months ago

Coherus Oncology: On The Shaping Up


Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 11:35 AM EDT - 2 months ago

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript


Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

May 12, 2025, 10:46 PM EDT - 5 months ago

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript


Coherus to Participate in Upcoming Investor Conferences

May 1, 2025, 5:04 PM EDT - 6 months ago

Coherus to Participate in Upcoming Investor Conferences


Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Dec 3, 2024, 9:34 AM EST - 11 months ago

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?


Coherus Completes Divestiture of Ophthalmology Franchise

Mar 4, 2024, 1:00 AM EST - 1 year ago

Coherus Completes Divestiture of Ophthalmology Franchise


Henry20feb_
Henry20feb_ Oct. 25 at 10:50 AM
$CHRS The Health Canada approval of LOQTORZI® (toripalimab) is a major milestone for Coherus BioSciences, expanding their immuno-oncology portfolio and strengthening their presence in the Canadian market. It provides a new treatment option for rare, aggressive cancers and opens opportunities for clinical collaborations, positioning Coherus for broader growth in oncology. (Thanks to ChatGPT)
1 · Reply
calibran_de
calibran_de Oct. 24 at 8:04 PM
0 · Reply
ITrustno1
ITrustno1 Oct. 24 at 8:01 PM
$CHRS low volume EOW finally, less than 50% avg. Earnings day variable on diff sites still: 11/6, & 2 sites showing 11/10th Fintel Reports -3.12% Short Interst for period ending 10/15/25 Borrow rate 1.35 Still over 30mill, but that’s 2straight months of negative SI (-2.44, -0.19, -2.29, & now -3.12) …& lowest total shares short since Jan 15th. Data share only: Do with it as you will.
1 · Reply
BMWLTWM3
BMWLTWM3 Oct. 24 at 6:29 PM
$CHRS what's up with you??
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Oct. 24 at 2:58 PM
$CHRS mm has nerfed all volatility. This shows the Penny stock rules. Jump up, retest down 35% down, jump up again, and settle into a wedge. Now chrs moving $0.04 cents today. Market likes $1.65-$1.68 where chrs is at cash $190-$200M market cap. Let's see if we close above 1.72
0 · Reply
normansteve
normansteve Oct. 24 at 2:09 PM
$CHRS It should be above $6, and here we are, at $1.X,65 😞 Someday we will see it above $6 💰
0 · Reply
normansteve
normansteve Oct. 24 at 2:07 PM
$CHRS Let's go, today +$1,80 🚀
0 · Reply
Gollum00
Gollum00 Oct. 24 at 2:05 PM
$CHRS how is this only up one cent with the news that just came out yesterday regarding Tori and Canada?
1 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Oct. 24 at 1:26 PM
$CHRS the stock will go up when no one expects it. They basically killing volatility more and more while volume decreases. Shorts are probably lots of mm who need to cover
0 · Reply
Jalu06
Jalu06 Oct. 24 at 12:23 PM
$CHRS I think 2026 can become transformational for coherus. Most important if coherus is participating at JPM Healthcare Conference in January and which timeslot they have. Unfortunately most of the HCC cases will have early response assessment so we can’t expect comparable complete responses rates. More important is I.e if less adverse events occur due to toripalimab in comparison with atezolizumab, this could hind for longer PFS and OS in later data cuts. CCR8 is something to watch in 2026, wen can expect some data readouts from major Pharma companies and I like the strategy „first to market“ in possible smaller indications, this could be of interest for mid sitze Pharma companies. I still assume that they have some kind of „pre deal“ with Junshi and Leo Pharma, but the real deal will only happen when the program is de risked and proof of concept is in. An other milestone payment could come in from GSK as the molecule name for SRF813 is Remzistotug
1 · Reply
Grandgustav
Grandgustav Oct. 24 at 12:07 PM
0 · Reply
normansteve
normansteve Oct. 24 at 10:10 AM
$CHRS Is there any news to expect before the end of the year? Thanks
1 · Reply
r_sr
r_sr Oct. 24 at 5:32 AM
$CHRS Apotex Receives Health Canada Approval for LOQTORZI® -- The First and Only Immuno-Therapy for Recurrent Unresectable or Metastatic Nasopharyngeal Cancer CHRS licensed it to Apotex in Canada https://www.prnewswire.com/news-releases/apotex-receives-health-canada-approval-for-loqtorzi--the-first-and-only-immuno-therapy-for-recurrent-unresectable-or-metastatic-nasopharyngeal-cancer-302591943.html Terms of the licence deal On June 27, 2024, Coherus entered into an exclusive Canadian license and distribution agreement with Apotex under which Apotex obtains rights to commercialize toripalimab in Canada. Up-front payment: Apotex agreed to pay Coherus US$ 6.25 million (or ~US$6.3 million) as an upfront fee. Milestone payments: Apotex will pay up to CAD $51.5 million in milestone payments tied to regulatory approvals and sales in Canada. Royalties: Apotex will pay Coherus a low double-digit percentage of net sales in Canada. Coherus in turn must pass on a portion of the royalties to its partner (Shanghai Junshi Biosciences Co., Ltd.) under their earlier agreement. Term: The agreement runs for 10 years following first commercial sale in Canada,
0 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Oct. 23 at 11:15 PM
$CHRS the weekly closing price has been about 1.66 every week since Sept 29 2025. If chrs closes at 1.66-1.68 again, it's 5 straight weeks locked up in this range. I looked back 5 years and COHERUS NEVER HAD SUCH LOW WEEKLY CLOSE VOLATILITY. penny stock rules definitely apply IMHO
1 · Reply
Jbaffs
Jbaffs Oct. 23 at 6:00 PM
$CHRS From GROK. I asked if everything went right. where could the stock be in two years. I'll take 17X Stock Price Projection for October 2027 Base Case (Multiples-Based): At $230M 2027 revenue, apply 7x EV/Revenue = $1.6B EV. Add $400M net cash (from divestiture + profits). Market cap: ~$2B$17/share (15x upside from $1.13). Bull Case (Full Success): If revenues hit $300M+ (e.g., all combos approved), 8x multiple (premium for IO leadership) → $2.4B EV + cash = $21/share. Scenario 2027 Revenue ($M) EV Multiple Projected Price/Share Upside from Current Base (Success) 230 7x $17 + 1,400% Ultra-Bull 300+ 8x $21 +1,760% Consensus (Mild) 150 6x $10 +785% . Conclusion If trials deliver clean data and toripalimab hits >$100M revenues, CHRS could transform from a distressed micro-cap (~$130M) to a $2B+ mid-cap by late 2027, trading at $17-$21/share. This values the company at ~7-8x forward sales, in line with growth biotechs (e.g., peers like Exelixis at 6-9x).
0 · Reply
cjwashington
cjwashington Oct. 23 at 4:58 PM
$CHRS is this thing broken, what the heck
1 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Oct. 23 at 1:25 PM
$CHRS wonder why Lanfear and Theresa going on a global tour...they are doing more conferences in Q3 and q4 2025 than in 2 years combined. They obviously looking for new money or funding or partners. Does Baird or Jefferies even cover coherus?
2 · Reply
normansteve
normansteve Oct. 23 at 1:13 PM
$CHRS Coherus Oncology to Participate in Upcoming Investor Conferences Oct 23, 2025 - UBS Global Healthcare Conference in Palm Beach Gardens, FL on Monday, November 10, 2025, at 1:15 p.m. Eastern Time / 10:15 a.m. Pacific Time - Jefferies Global Healthcare Conference in London, England on Tuesday, November 18, 2025, at 10:30 a.m. Greenwich Mean Time / 5:30 a.m. Eastern Time - Baird Biotech Discovery Series takes place virtually on Wednesday, December 17, 2025, at 1:30 p.m. Eastern Time / 10:30 a.m. Pacific Time https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-participate-upcoming-investor-conferences-0
0 · Reply
GoWhiteSox
GoWhiteSox Oct. 23 at 12:34 PM
$CHRS https://investors.coherus.com/news-releases/news-release-details/coherus-oncology-participate-upcoming-investor-conferences-0
0 · Reply
Grandgustav
Grandgustav Oct. 23 at 12:22 PM
0 · Reply
AlaInvest22222
AlaInvest22222 Oct. 22 at 7:37 PM
$CHRS No information on today's event???
1 · Reply
Jack_Nicholson_Truth
Jack_Nicholson_Truth Oct. 22 at 4:37 PM
$CHRS gap is closed. Likely more shorting. Only time will tell
0 · Reply